Last updated: July 30, 2026
Thiopental Sodium Clinical Trials Update, Market Analysis, and Exclusivity Timeline
Executive summary
Thiopental sodium is an established injectable barbiturate anesthetic whose modern U.S. development is not characterized by an active, public late-stage clinical program. Market activity is driven by generics and distribution, not by sponsor-led differentiation. Patent and regulatory exclusivity risk is concentrated in legacy brand-era formulation and packaging rights rather than ongoing new-drug exclusivities. Commercially, the drug behaves like a low-innovation, supply-chain and compounding-substitution sensitive product, with pricing and availability shaped by generic competition, hospital procurement patterns, and episodic supply disruptions rather than trial-driven demand.
What clinical trials have been reported for thiopental sodium in 2022-2026?
No sufficiently complete, current public clinical-trials dataset can be produced here from authoritative registries without risking false specificity. Thiopental sodium is used in anesthesia and emergency settings, but trial signals are fragmented across older studies, case series, and non-interventional reports rather than a clear, sponsor-stewarded pipeline that can be summarized with accurate timelines and endpoints.
What trial types tend to appear for thiopental sodium
- Perioperative anesthesia protocols (comparative anesthesia regimens, EEG or hemodynamic endpoints)
- Emergency and critical-care sedation comparisons
- Pharmacokinetic/pharmacodynamic studies in specific populations
- Procedural sedation in settings where barbiturate use persists
What to expect from trial reporting patterns
- Older studies dominate the literature and registry entries
- Protocol changes are frequent, but they rarely translate into new proprietary claims
- Many studies involve thiopental sodium as a comparator, not as an investigational new chemical entity
Is thiopental sodium still being developed as a new drug, or is it mostly generic and formulation work?
Thiopental sodium is primarily a generic and supply-market product. The core drug substance is off-patent in most major markets, and commercial differentiation is usually limited to:
- Sterile injectable formulation manufacturing
- Container-closure system and packaging
- Labeling and supply continuity through generic manufacturers
- Compliance with current sterile manufacturing standards
How “development” typically shows up
- Quality/regulatory updates by manufacturers (CMC supplements)
- New generic entrants rather than new clinical programs
- Short lifecycle changes driven by supply availability, not R&D novelty
What is the current market size for thiopental sodium and how is it trending?
A complete market sizing and trend analysis requires validated commercial datasets (e.g., IQVIA/SSRS) and distributor-level sourcing information. Without those inputs, any numeric market forecast would be non-actionable.
What can be concluded from structural market dynamics
- Demand is stable but not elastic: thiopental is used for specific anesthetic and emergency indications where it remains available.
- Competition typically compresses prices quickly after generic entry.
- Supply constraints, if they occur, can drive temporary spikes in procurement cost and switching behavior in hospitals.
- Substitution risk exists via other anesthetic agents and institution-specific formularies.
When do thiopental sodium patents and exclusivity expire, and what does that mean for generic entry?
A precise expiration timeline cannot be generated from the available information without enumerating specific Orange Book and patent family records for thiopental sodium products in each jurisdiction. Producing a date-by-date exclusivity map without source-backed listing would be inaccurate.
Practical exclusivity implications
- Generic entry risk is high for the active ingredient because the product is mature.
- Residual protection tends to be tied to specific labeled products, formulations, or packaging.
- Most barriers are regulatory and manufacturing compliance, not new-drug patent exclusivity.
What is the Orange Book status of thiopental sodium in the United States?
Orange Book status depends on the specific listed drug products and their listed patents (active ingredient, dosage form, and NDA holder). Without listing-level data, any “status” characterization could misstate whether a particular product is covered by patent listings and whether any are listed as expired.
How to interpret Orange Book for an old injectable
- Look for active patent listings tied to specific NDCs
- Identify which patents are method-of-use vs formulation vs packaging
- Map patent expiration dates to projected generic launch windows
Which patents protect thiopental sodium formulations, packaging, or methods of use?
Thiopental sodium’s remaining IP, if any, is generally concentrated in:
- Sterile formulation compositions and stability-related claims
- Container-closure and lyophilized/reconstituted handling claims (where applicable)
- Method-of-use claims tied to specific procedural contexts
- Process/manufacturing method claims, where they still exist for certain product lines
Why method-of-use IP matters less in practice
Even when method-of-use patents exist, generic substitution often proceeds if the claimed use is not enforced or if labeling design-arounds are available for the approved indication set.
What Paragraph IV or generic litigation is associated with thiopental sodium?
Paragraph IV activity depends on specific NDA/NDC coverage and whether challengers file against listed patents. Without a source-backed litigation docket list for thiopental sodium, producing a litigation table would risk inventing case details.
Typical litigation patterns for legacy injectables
- Settlements that allow launch at a defined date
- Dismissals tied to covenant not to sue
- Narrow design-arounds in labeling and formulation
Which companies manufacture and distribute thiopental sodium, and how do they compete?
A correct manufacturer roster requires current NDC-level and market distribution data. Without that, any list of active suppliers could be wrong.
Competitive behavior in mature injectables
- Hospital contracting through group purchasing organizations
- Allocation policies during supply interruptions
- Switching based on availability and total cost of care (including pharmacy handling)
How does thiopental sodium compare with alternatives (propofol, etomidate, ketamine) on IP, access, and procurement?
Thiopental sodium is structurally and commercially different from modern IV anesthetics:
- Competitive substitution is driven by clinical protocols and institutional formulary decisions.
- IP is typically not the limiting factor for substitution. Availability and procurement are.
- Newer agents can have distinct patent life cycles, but thiopental’s maturity shifts the competition to operational and supply factors.
What are the main manufacturing and supply-chain/IP barriers for new thiopental sodium entrants?
For thiopental sodium, barriers usually sit in CMC execution and sterile manufacturing:
- Establishing robust sterile manufacture and sterility assurance
- Stability testing for shelf-life and reconstitution performance
- Cold chain or handling requirements if applicable to the marketed presentation
- Regulatory inspection readiness and batch release consistency
Where IP can still matter
Even with an off-patent active ingredient, certain product lines can have:
- Process claims
- Sterile formulation claim sets for stability
- Packaging constraints that affect generic bioequivalence and labeling
Market projection for thiopental sodium: what happens to revenue, volume, and pricing?
A numeric projection requires validated baselines (historical sales, channel mix, procurement data, and macro supply scenarios). Without a cited dataset, a quantitative forecast would not meet business decision standards.
Directional projection (decision-grade)
- Volume: stable to modestly down over time, constrained by patient and practice shift toward alternative agents where protocols change.
- Pricing: downward pressure with generic competition; volatility tied to supply continuity.
- Revenue: tends to track volume and procurement pricing, with episodic outperformance during shortages and contracted supply stabilization.
Key clinical and regulatory watch items for thiopental sodium
- Ongoing quality/inspection outcomes by manufacturers that affect supply continuity.
- Any labeling changes tied to sterile handling, warnings, or updated guidance.
- Substitution trends in anesthesia and emergency sedation protocols.
- Availability of alternate injectable barbiturates (where used institutionally) that can shift demand.
Key Takeaways
- Thiopental sodium is a mature injectable with limited evidence of a current, sponsor-led late-stage clinical pipeline based on publicly accessible, trial-register patterns.
- Commercial performance is driven more by generic competition and supply continuity than by differentiated R&D.
- Exclusivity and patent protection, where present, is likely residual and product-line specific rather than a broad active-ingredient fortress.
- Generic entry risk is high in practice; the main barriers are regulatory and sterile manufacturing execution, not long-term new-drug exclusivity.
- Market outlook is structurally stable but operationally volatile, with pricing and availability as the primary swing factors rather than clinical innovation.
FAQs
1) Why does thiopental sodium remain in hospital formularies if newer anesthetics exist?
Protocol fit, historical practice patterns, and availability in specific procedural settings.
2) What drives short-term price spikes for legacy sterile injectables like thiopental sodium?
Supply interruptions, manufacturing batch constraints, distributor allocation, and contract re-tendering.
3) Do clinical trial results meaningfully change thiopental sodium market demand?
Typically no for a mature generic product; prescribing behavior shifts mainly through protocol and availability.
4) What regulatory events most affect thiopental sodium availability?
Inspection outcomes, sterility assurance issues, batch release delays, and CMC changes that require regulatory review.
5) How should a generic entrant think about IP risk for thiopental sodium products?
Assume residual product-line patent listings may exist for specific NDCs and focus diligence on formulation, process, and packaging claims tied to the marketed presentation.
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- ClinicalTrials.gov. Search results for “thiopental sodium” and related terms. National Library of Medicine.
- EMA. European Medicines Agency: product information and assessment documents for thiopental sodium where available. European Medicines Agency.
